Login to Your Account



Abgenix Drops ABX-IL8 For RA Following Phase II Trial Results

By Kim Coghill


Monday, January 7, 2002
Abgenix Inc. s stock took a small hit Friday following the disclosure that a Phase IIa study of its rheumatoid arthritis candidate failed to meet its endpoints.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription